Eduardo Yáñez
Universidad de La Frontera(CL)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, Lymphoma Diagnosis and Treatment, Endometrial and Cervical Cancer Treatments, Chronic Lymphocytic Leukemia Research, HER2/EGFR in Cancer Research
Most-Cited Works
- → Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial(2020)310 cited
- → Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial(2021)132 cited
- → Lenvatinib plus pembrolizumab for patients with previously treated biliary tract cancers in the multicohort phase II LEAP-005 study.(2021)68 cited
- → LEAP-005: A phase II multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors—Results from the colorectal cancer cohort.(2021)66 cited
- → Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer(2023)46 cited
- → Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients(2017)46 cited
- → Preoperative Chemoradiotherapy in the Treatment of Gallbladder Cancer(1999)38 cited
- → Pembrolizumab plus chemotherapy for advanced and recurrent cervical cancer: final analysis according to bevacizumab use in the randomized KEYNOTE-826 study(2024)37 cited
- → Phase III study of veliparib with carboplatin and paclitaxel in HER2-negative advanced/metastatic gBRCA-associated breast cancer(2019)32 cited
- → Lenvatinib plus pembrolizumab for patients with previously treated biliary tract cancers in the multicohort phase 2 LEAP-005 study.(2021)26 cited